Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response

Gut and Liver

Volumn 10, Issue 3, 2016, Pages 429-436

  Lee, Hye Won ^a   Chon, Young Eun ^a   Kim, Seung Up ^a   Kim, Beom Kyung ^a   Park, Jun Yong ^a   Kim, Do Young ^a   Ahn, Sang Hoon ^a   Jung, Kyu Sik ^a   Park, Young Nyun ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Carcinoma; Chronic; Hepatitis C; Hepatocellular; Liver stiffness; Sustained virological response; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; MIPEGINTERFERON ALPHA2B; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; AGE; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE MARKER; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS GENOTYPE 1; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER RELATED EVENT; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGICAL RESPONSE; TRANSIENT ELASTOGRAPHY; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; COMPLICATION; HEPATITIS C, CHRONIC; LIVER TUMOR; PREGNANCY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREGNANCY; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS;

EID: 84969166469     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15021     Document Type: Article

References (26)

1. Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-2798
2. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study. Hepatology 2010;51:2069-2076
3. Fernández-Rodríguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCVrelated cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010;105:2164-2172
4. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587
5. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013;57:230-236
6. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-844
7. Masuzaki R, Yoshida H, Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 2010;78 Suppl 1:17-23
8. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49:1954-1961
9. Toccaceli F, Laghi V, Capurso L, et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003;10:126-133
10. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403
11. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int 2011;31 Suppl 1:13-17
12. Amorim TG, Staub GJ, Lazzarotto C, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol 2012;11:855-861
13. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-659
14. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTestTM) and transient elastography (FibroScan?). J Hepatol 2014;60:706-714
15. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713
16. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-1302.e4
17. D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013;59:251-256
18. Chon YE, Jung ES, Park JY, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 2012;46:518-525
19. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885-894
20. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
21. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010;52:518-527
22. Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2014;12:1186-1195
23. Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fibrosis: regression with therapy. Aliment Pharmacol Ther 2008;28:1175-1187
24. Asahina Y, Tsuchiya K, Nishimura T, et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013;58:1253-1262
25. Bari K, Sharma P. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3. Gastroenterology 2014;147:534-536
26. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887